Контрацепция при антифосфолипидном синдроме и системной красной волчанке (по рекомендациям Европейского альянса ревматологических ассоциаций/Американской коллегии ревматологов, EULAR/АCR)

Одной из первостепенных задач общества является сохранение и укрепление здоровья нации. Недостаточное понимание важности вопросов контрацепции медицинским сообществом и ее применения социумом может привести к нарушению репродуктивного здоровья населения. Базовые знания об эффективных и безопасных методах контрацепции важны для каждого ревматолога, поскольку репродуктивное здоровье влияет как на общее состояние больных, так и на течение основного ревматического заболевания (РЗ). Это особенно касается больных, позитивных по антифосфолипидным антителам (аФЛ), пациентов с антифосфолипидным синдромом (АФС) и системной красной волчанкой (СКВ). Наличие аФЛ/АФС, как и активность СКВ, является наиболее важным фактором, определяющим выбор метода контрацепции и риск применения гормональных контрацептивов при РЗ. Между тем, использование адекватной (высокоэффективной и безопасной) контрацепции у данной категории пациентов позволяет не только планировать рождение ребенка, но и избежать нежелательной беременности в активной фазе болезни, приема эмбриотоксических и тератогенных препаратов, а также проводить оптимальное лечение сопутствующей патологии, о чем должен быть хорошо осведомлен курирующий врач-ревматолог. Рассмотрению основных вопросов контрацепции у наиболее «ранимой» категории больных РЗ, имеющих аФЛ, АФС и СКВ, посвящена данная публикация.

1. Обоскалова ТА (ред). Методы контрацепции и критерии их применения. Учебное пособие. Екатеринбург;2019.

2. Национальные медицинские критерии приемлемости методов контрацепции. Адаптированный документ «Медицинские критерии приемлемости использования методов контрацепции ВОЗ, 5-е издание, 2015». М.;2023.

3. Сухих ГТ, Прилепская ВН, Аганезова НВ, Андреева ЕН, Баранов ИИ, Долгушина НВ, и др. Контрацепция у женщин репродуктивного возраста. Учебное пособие. М.:Бином;2019.

4. Сумятина ЛВ. Современные гормональные контрацептивы: новые возможности выбора. Проблемы репродукции. 2014;(6): 46-48.

5. Trussell J. Contraceptive failure in the United States. Contraception. 2011;83(5):397-404. doi: 10.1016/j.contraception.2011.01.021

6. Kestelman P, Trussell J. Efficacy of the simultaneous use of condoms and spermicides. Fam Plan Perspect. 1991;23(5):226-227,232.

7. Назарова НМ, Прилепская ВН. Эстроген-гестагенные рилизинг-системы: новый взгляд на контрацепцию (обзор литературы). Фарматека. 2009;(14):10-16.

8. Williams WV. Hormonal contraception and the development of autoimmunity: A review of the literature. Linacre Q. 2017;84(3): 275-295. doi: 10.1080/00243639.2017.1360065

9. Iwata M, Oikawa Y, Shimizu Y, Sakashita N, Shoji A, Igarashi A, et al. Efficacy of low-dose estrogen-progestins and progestins in Japanese women with dysmenorrhea: A systematic review and network meta-analysis. Adv Ther. 2022;39(11):4892-4909. doi: 10.1007/s12325-022-02298-9

10. Прилепская ВН. Новаринг – контрацепция, анатомия, сексология. Гинекология. 2004;6(6):306-308.

11. Прилепская ВН, Назарова НМ. Новые технологии в контрацепции: гормональные рилизинг-системы. Гинекология. 2005;7(1):41-44.

12. Khialani D, Rosendaal F, Vlieg AVH. Hormonal contraceptives and the risk of venous thrombosis. Semin Thromb Hemost. 2020;46(8):865-871. doi: 10.1055/s-0040-1715793

13. Medical Eligibility Criteria for Contraceptive Use. 5th ed. Geneva: World Health Organization; 2015. https://ww.who.int/reproductivehealth/publications/family_planning/Ex-Summ-MEC-5/en/

14. Amy JJ, Tripathi V. Contraception for women: An evidence-based overview. BMJ. 2009;339:b2895. doi: 10.1136/bmj.b2895

15. Winner B, Peipert JF, Zhao Q, Buckel C, Madden T, Allsworth JE, et al. Effectiveness of long-acting reversible contraception. N Engl J Med. 2012;366(21):1998-2007. doi: 10.1056/NEJMoa1110855

16. Kavanaugh ML, Pliskin E. Use of contraception among reproductive-aged women in the United States, 2014 and 2016. F S Rep. 2020;1(2):83-93. doi: 10.1016/j.xfre.2020.06.006

17. Sammaritano LR, Bermas BL, Chakravarty EE, Chambers C, Clowse MEB, Lockshin MD, et al. 2020 American College of Rheumatology guideline for the management of reproductive health in rheumatic and musculoskeletal diseases. Arthritis Care Res (Hoboken). 2020;72(4):461-488. doi: 10.1002/acr.24130

18. Насонов ЕЛ (ред.). Антифосфолипидный синдром. М.:Литтерра;2004.

19. Решетняк ТМ. Антифосфолипидный синдром: диагностика и клинические проявления (лекция). Научно-практическая ревматология. 2014;52(1):56-71. doi: 10.14412/1995-4484-2014-56-71

20. Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. 2006;4(2):295-306. doi: 10.1111/j.1538-7836.2006.01753.x

21. Schwarz EB, Manzi S. Risk of unintended pregnancy among women with systemic lupus erythematosus. Arthritis Rheum. 2008;59(6):863-866. doi: 10.1002/art.23712

22. Yazdany J, Trupin L, Kaiser R, Schmajuk G, Gillis JZ, Chakravarty E, et al. Contraceptive counseling and use among women with systemic lupus erythematosus: A gap in health care quality? Arthritis Care Res (Hoboken). 2011;63(3):358-365. doi: 10.1002/acr.20402

23. Brunson MR, Klein DA, Olsen CH, Weir LF, Roberts TA. Postpartum contraception: Initiation and effectiveness in a large universal healthcare system. Am J Obstet Gynecol. 2017;217(1): 55.e1-55.e9. doi: 10.1016/j.ajog.2017.02.036

24. Mendel A, Bernatsky S, Pineau CA, St-Pierre Y, Hanly JG, Urowitz MB, et al. Use of combined hormonal contraceptives among women with systemic lupus erythematosus with and without medical contraindications to oestrogen. Rheumatology (Oxford). 2019;58(7):1259-1267. doi: 10.1093/rheumatology/kez014

25. DeNoble AE, Hall KS, Xu X, Zochowski MK, Piehl K, Dalton VK. Receipt of prescription contraception by commercially insured women with chronic medical conditions. Obstet Gynecol. 2014;123(6):1213-1220. doi: 10.1097/AOG.0000000000000279

26. Champaloux SW, Tepper NK, Curtis KM, Zapata LB, Whiteman MK, Marchbanks PA, et al. Contraceptive use among women with medical conditions in a nationwide privately insured population. Obstet Gynecol. 2015;126(6):1151-1159. doi: 10.1097/AOG.0000000000001134

27. Birru Talabi M, Clowse MEB, Blalock SJ, Moreland L, Siripong N, Borrero S. Contraception use among reproductive-age women with rheumatic diseases. Arthritis Care Res (Hoboken). 2019;71(8):1132-1140. doi: 10.1002/acr.23724

28. Danowski A, de Azevedo MN, de Souza Papi JA, Petri M. Determinants of risk for venous and arterial thrombosis in primary antiphospholipid syndrome and in antiphospholipid syndrome with systemic lupus erythematosus. J Rheumatol. 2009;36(6):1195-1199. doi: 10.3899/jrheum.081194

29. Erkan D, Harrison MJ, Levy R, Peterson M, Petri M, Sammaritano L, et al. Aspirin for primary thrombosis prevention in the antiphospholipid syndrome: A randomized, double-blind, placebo-controlled trial in asymptomatic antiphospholipid antibody-positive individuals. Arthritis Rheum. 2007;56(7):2382-2391. doi: 10.1002/art.22663

30. Brouwer JL, Bijl M, Veeger NJ, Kluin-Nelemans HC, van der Meer J. The contribution of inherited and acquired thrombophilic defects, alone or combined with antiphospholipid antibodies, to venous and arterial thromboembolism in patients with systemic lupus erythematosus. Blood. 2004;104(1):143-148. doi: 10.1182/blood-2003-11-4085

31. Girolami A, Zanon E, Zanardi S, Saracino MA, Simioni P. Thromboembolic disease developing during oral contraceptive therapy in young females with antiphospholipid antibodies. Blood Coagul Fibrinolysis. 1996;7(4):497-501. doi: 10.1097/00001721-199606000-00011

32. Bacci S, Urquiola G, del Médico P, Sanabria JA, Bacci JC, Guzmán M, et al. Síndrome de Budd-Chiari, tromboembolismo pulmonar y trombosis venosa profunda, asociado con “anticoagulante lúpico” y uso reciente de anticonceptivos orales [Budd-Chiari syndrome, pulmonary thromboembolism, and deep venous thrombosis associated with “lupus anticoagulant” and recent use of oral contraceptives]. G E N. 1990;44(3):237-242 (In Spanish).

33. Urbanus RT, Siegerink B, Roest M, Rosendaal FR, de Groot PG, Algra A. Antiphospholipid antibodies and risk of myocardial infarction and ischaemic stroke in young women in the RATIO study: A case-control study. Lancet Neurol. 2009;8(11):998-1005. doi: 10.1016/S1474-4422(09)70239-X

34. Sammaritano LR.Which hormones and contraception for women with APS? Exogenous hormone use in women with APS. Curr Rheumatol Rep. 2021;23(6):44. doi: 10.1007/s11926-021-01006-w

35. Iskander MK, Khan M. Chorea as the initial presentation of oral contraceptive related systemic lupus erythematosus. J Rheumatol. 1989;16(6):850-851.

36. Yamakami LY, de Araujo DB, Silva CA, Baracat EC, de Carvalho JF. Severe hemorrhagic corpus luteum complicating anticoagulation in antiphospholipid syndrome. Lupus. 2011;20(5):523-526. doi: 10.1177/0961203310383300

37. Crétel E, Cacoub P, Huong DL, Gompel A, Amoura Z, Piette JC. Massive ovarian haemorrhage complicating oral anticoagulation in the antiphospholipid syndrome: A report of three cases. Lupus. 1999;8(6):482-485. doi: 10.1177/096120339900800614

38. ACOG Committee on Practice Bulletins-Gynecology. ACOG practice bulletin. No. 73: Use of hormonal contraception in women with coexisting medical conditions. Obstet Gynecol. 2006;107(6):1453-1472. doi: 10.1097/00006250-200606000-00055

39. Pisoni CN, Cuadrado MJ, Khamashta MA, Hunt BJ. Treatment of menorrhagia associated with oral anticoagulation: Efficacy and safety of the levonorgestrel releasing intrauterine device (Mirena coil). Lupus. 2006;15(12):877-880. doi: 10.1177/0961203306071706

40. Rebelo RC, Pignaton E, Valeria Bahamondes M, Costallat LTL, Appenzeller S, Bahamondes L, et al. Disease activity and thromboembolic events in women with systemic lupus erythematosus with and without anti-phospholipid syndrome: Users of the 52-mg levonorgestrel-releasing intrauterine system. Arch Gynecol Obstet. 2019;299(6):1597-1605. doi: 10.1007/s00404-019-05131-x

41. van Vlijmen EF, Veeger NJ, Middeldorp S, Hamulyák K, Prins MH, Büller HR, et al. Thrombotic risk during oral contraceptive use and pregnancy in women with factor V Leiden or prothrombin mutation: A rational approach to contraception. Blood. 2011;118(8):2055-2061;quiz 2375. doi: 10.1182/blood-2011-03-345678

42. Klok FA, Barco S. Optimal management of hormonal contraceptives after an episode of venous thromboembolism. Thromb Res. 2019;181(Suppl 1):1-5. doi: 10.1016/S0049-3848(19)30357-3

43. Martinelli I, Lensing AW, Middeldorp S, Levi M, Beyer-Westendorf J, van Bellen B, et al. Recurrent venous thromboembolism and abnormal uterine bleeding with anticoagulant and hormone therapy use. Blood. 2016;127(11):1417-1425. doi: 10.1182/blood2015-08-665927

44. Паневин ТС, Попкова ТВ, Решетняк ТМ, Кошелева НМ, Ледина АВ. Менопаузальная гормонотерапия при системной красной волчанке: Pro et contra. Научно-практическая ревматология. 2023;61(1):70-76. doi: 10.47360/1995-4484-2023-70-76

45. The NAMS 2017 Hormone Therapy Position Statement Advisory Panel. The 2017 hormone therapy position statement of The North American Menopause Society. Menopause. 2017;24(7):728-753. doi: 10.1097/GME.0000000000000921

46. U.S. Preventive Services Task Force. Hormone therapy for the prevention of chronic conditions in postmenopausal women: Recommendations from the U.S. Preventive Services Task Force. Ann Intern Med. 2005;142(10):855-860.

47. Beral V; Million Women Study Collaborators. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet. 2003;362(9382):419-427. doi: 10.1016/s0140-6736(03)14065-2

48. Менопауза и климактерическое состояние у женщин: Клинические рекомендации МЗ РФ. М.;2021. [Menopause and climacteric condition in women. Clinical recommendations of the Ministry of Health of the Russian Federation. Moscow;2021 (In Russ.)].

49. Cushman M, Kuller LH, Prentice R, Rodabough RJ, Psaty BM, Stafford RS, et al.; Women’s Health Initiative Investigators. Estrogen plus progestin and risk of venous thrombosis. JAMA. 2004;292(13):1573-1580. doi: 10.1001/jama.292.13.1573

50. Marjoribanks J, Farquhar C, Roberts H, Lethaby A. Long term hormone therapy for perimenopausal and postmenopausal women. Cochrane Database Syst Rev. 2012;(7):CD004143. doi: 10.1002/14651858

51. Smith NL, Heckbert SR, Lemaitre RN, Reiner AP, Lumley T, Weiss NS, et al. Esterified estrogens and conjugated equine estrogens and the risk of venous thrombosis. JAMA. 2004;292(13):1581-1587. doi: 10.1001/jama.292.13.1581

52. Sweetland S, Beral V, Balkwill A, Liu B, Benson VS, Canonico M, et al.; Million Women Study Collaborators. Venous thromboembolism risk in relation to use of different types of postmenopausal hormone therapy in a large prospective study. J Thromb Haemost. 2012;10(11):2277-2286. doi: 10.1111/j.1538-7836.2012.04919.x

53. Straczek C, Oger E, Yon de Jonage-Canonico MB, Plu-Bureau G, Conard J, Meyer G, et al.; Estrogen and Thromboembolism Risk (ESTHER) Study Group. Prothrombotic mutations, hormone therapy, and venous thromboembolism among postmenopausal women: Impact of the route of estrogen administration. Circulation. 2005; 112(22):3495-3500. doi: 10.1161/CIRCULATIONAHA.105.565556

54. Rosendaal FR, Vessey M, Rumley A, Daly E, Woodward M, Helmerhorst FM, et al. Hormonal replacement therapy, prothrombotic mutations and the risk of venous thrombosis. Br J Haematol. 2002;116(4):851-854. doi: 10.1046/j.0007-1048.2002.03356.x

55. Canonico M, Oger E, Plu-Bureau G, Conard J, Meyer G, Lévesque H, et al.; Estrogen and Thromboembolism Risk (ESTHER) Study Group. Hormone therapy and venous thromboembolism among postmenopausal women: Impact of the route of estrogen administration and progestogens: The ESTHER study. Circulation. 2007;115(7):840-845. doi: 10.1161/CIRCULATIONAHA.106.642280

56. Rovinski D, Ramos RB, Fighera TM, Casanova GK, Spritzer PM. Risk of venous thromboembolism events in postmenopausal women using oral versus non-oral hormone therapy: A systematic review and meta-analysis. Thromb Res. 2018;168:83-95. doi: 10.1016/j.thromres.2018.06.014

57. Canonico M, Plu-Bureau G, Lowe GD, Scarabin PY. Hormone replacement therapy and risk of venous thromboembolism in postmenopausal women: Systematic review and meta-analysis. BMJ. 2008;336(7655):1227-1231. doi: 10.1136/bmj.39555.441944.BE

58. Pinkerton JV, James AH. Management of menopausal symptoms for women who are at high risk of thrombosis. Clin Obstet Gynecol. 2018;61(2):260-268. doi: 10.1097/GRF.0000000000000358

59. Krause MS, Nakajima ST. Hormonal and nonhormonal treatment of vasomotor symptoms. Obstet Gynecol Clin North Am. 2015;42(1):163-179. doi: 10.1016/j.ogc.2014.09.008

60. Nelson HD, Vesco KK, Haney E, Fu R, Nedrow A, Miller J, et al. Nonhormonal therapies for menopausal hot flashes: Systematic review and meta-analysis. JAMA. 2006;295(17):2057-2071. doi: 10.1001/jama.295.17.2057

61. Management of symptomatic vulvovaginal atrophy: 2013 position statement of The North American Menopause Society. Menopause. 2013;20(9):888-902;quiz 903-904. doi: 10.1097/GME.0b013e3182a122c2

62. Bhupathiraju SN, Grodstein F, Stampfer MJ, Willett WC, Crandall CJ, Shifren JL, et al. Vaginal estrogen use and chronic disease risk in the Nurses’ Health Study. Menopause. 2018;26(6):603-610. doi: 10.1097/GME.0000000000001284

63. de Melo AS, Dos Reis RM, Ferriani RA, Vieira CS. Hormonal contraception in women with polycystic ovary syndrome: Choices, challenges, and noncontraceptive benefits. Open Access J Contracept. 2017;8:13-23. doi: 10.2147/OAJC.S85543

64. Vercellini P, Buggio L, Frattaruolo MP, Borghi A, Dridi D, Somigliana E. Medical treatment of endometriosis-related pain. Best Pract Res Clin Obstet Gynaecol. 2018;51:68-91. doi: 10.1016/j.bpobgyn.2018.01.015

65. Yuk JS, Song JY, Lee JH, Park WI, Ahn HS, Kim HJ. Levonorgestrel-releasing intrauterine systems versus oral cyclic medroxyprogesterone acetate in endometrial hyperplasia therapy: A meta-analysis. Ann Surg Oncol. 2017;24(5):1322-1329. doi: 10.1245/s10434-016-5699-9

66. Grandone E, Di Micco PP, Villani M, Colaizzo D, FernándezCapitán C, Del Toro J, et al.; RIETE Investigators. Venous thromboembolism in women undergoing assisted reproductive technologies: Data from the RIETE registry. Thromb Haemost. 2018;118(11):1962-1968. doi: 10.1055/s-0038-1673402

67. Machin N, Ragni MV. Hormones and thrombosis: Risk across the reproductive years and beyond. Transl Res. 2020;225:9-19. doi: 10.1016/j.trsl.2020.06.011

68. Xu X, Chlebowski RT, Shi J, Barac A, Haque R. Aromatase inhibitor and tamoxifen use and the risk of venous thromboembolism in breast cancer survivors. Breast Cancer Res Treat. 2019;174(3):785-794. doi: 10.1007/s10549-018-05086-8

69. Getahun D, Nash R, Flanders WD, Baird TC, Becerra-Culqui TA, Cromwell L, et al. Cross-sex hormones and acute cardiovascular events in transgender persons: A cohort study. Ann Intern Med. 2018;169(4):205-213. doi: 10.7326/M17-2785

70. Goldstein Z, Khan M, Reisman T, Safer JD. Managing the risk of venous thromboembolism in transgender adults undergoing hormone therapy. J Blood Med. 2019;10:209-216. doi: 10.2147/JBM.S166780

71. Duan B, Zhang Y, Wang X, Zhang Y, Hou Y, Bai J, et al. Effect of megestrol acetate combined with oral nutrition supplement in malnourished lung cancer patients: A single-center prospective cohort study. Front Nutr. 2021;8:654194. doi: 10.3389/fnut.2021.654194

72. Poulter NR, Chang CL, Farley TM, Meirik O. Risk of cardiovascular diseases associated with oral progestagen preparations with therapeutic indications. Lancet. 1999;354(9190):1610. doi: 10.1016/s0140-6736(99)03132-3

73. Аномальные маточные кровотечения. Клинические рекомендации МЗ РФ. М.;2021. [Abnormal uterine bleeding. Clinical recommendations of the Ministry of Health of the Russian Federation. Moscow;2021 (In Russ.)].